PHYTO-3

Serial Number 87523966
602

Registration Progress

Application Filed
Jul 11, 2017
Under Examination
Nov 7, 2017
Approved for Publication
Sep 12, 2017
Published for Opposition
Sep 12, 2017
Registered

Trademark Image

PHYTO-3

Basic Information

Serial Number
87523966
Filing Date
July 11, 2017
Published for Opposition
September 12, 2017
Abandonment Date
April 16, 2019
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
602
Status Date
May 11, 2019
Classes
005

Rights Holder

Marine Ingredients LLC

16
Address
794 Sunrise Blvd.
Mount Bethel, PA 18343

Ownership History

Marine Ingredients LLC

Original Applicant
16
Mount Bethel, PA

Marine Ingredients LLC

Owner at Publication
16
Mount Bethel, PA

Legal Representation

Attorney
Gary D.E. Pierce

USPTO Deadlines

All Deadlines Cleared

All 8 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

31 events
Date Code Type Description Documents
May 13, 2019 MAB2 E ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND Loading...
May 11, 2019 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Oct 13, 2018 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Oct 13, 2018 GNFR O FINAL REFUSAL E-MAILED Loading...
Oct 13, 2018 CNFR W SU - FINAL REFUSAL - WRITTEN Loading...
Sep 19, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 18, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 18, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 13, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Sep 13, 2018 GNRT O NON-FINAL ACTION E-MAILED Loading...
Sep 13, 2018 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Sep 10, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 6, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 7, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 6, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 6, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 13, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 13, 2018 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 13, 2018 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
May 23, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
May 23, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
May 1, 2018 IUAF S USE AMENDMENT FILED Loading...
May 1, 2018 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Nov 7, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 12, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 12, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 23, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 4, 2017 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 3, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 18, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 14, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary and nutritional supplements; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary food supplements; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary supplements; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary supplements for improving cognitive function; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary supplements for reducing inflammation; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary supplements for managing symptoms of PTSD; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of dietary supplements for managing opioid withdrawal; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of pharmaceutical preparations for the treatment of and for improving cognitive function; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of pharmaceutical preparations for the treatment of and for reducing inflammation; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of pharmaceutical preparations for the treatment of and for managing opioid withdrawal; Omega-3 and extracts from hemp-derived CBD sold as a component ingredient of pharmaceutical preparations for the treatment of and for managing symptoms of PTSD
First Use Anywhere: Dec 15, 2017
First Use in Commerce: Dec 15, 2017

Classification

International Classes
005